Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 12/20 | 0.53 |
| ▸ | ESR1 | P03372 | 11/20 | 0.53 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.49 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.48 |
| ▸ | ABL1 | P00519 | 2/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.46 |
| ▸ | BCR | P11274 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2965864 | 0.91 | PDK2 (0.43) | PDK2 | |
| SCHEMBL13700678 | 0.87 | PDK2 (0.60) | ESR2ESR1PDK2ABL1ABCB1 | |
| SCHEMBL27864761 | 0.87 | LPL (0.44) | ESR2ESR1HSD17B1HSD17B2CYP1A2 | |
| SCHEMBL26250566 | 0.84 | ESR2 (0.56) | ESR2ESR1HSD17B1HSD17B2CYP1A2 | |
| SCHEMBL14506088 | 0.84 | ESR2 (0.56) | ESR2ESR1HSD17B1HSD17B2CYP1A2 | |
| SCHEMBL21383381 | 0.84 | HSD17B1 (0.50) | ESR2ESR1HSD17B1HSD17B2CYP1A2 | |
| SCHEMBL16025179 | 0.84 | ESR2 (0.41) | ESR2ESR1HSD17B1HSD17B2CYP1A2 | |
| SCHEMBL29638162 | 0.84 | PDK2 (0.56) | ESR2ESR1CYP3A4CYP2C19PDK2 | |
| SCHEMBL9936511 | 0.84 | PDK2 (0.56) | ESR2ESR1CYP3A4CYP2C19PDK2 | |
| SCHEMBL1649136 | 0.83 | PDK2 (0.47) | PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9331296-B2 | Organic light-emitting device | CANON KABUSHIKI KAISHA (JP) | 2016-05-03 | — | — | US | disclosed |
| US-9331296-B2 | Organic light-emitting device | CANON KABUSHIKI KAISHA (JP) | 2016-05-03 | — | — | US | disclosed |
| US-20130001542-A1 | ORGANIC LIGHT-EMITTING DEVICE | CANON KABUSHIKI KAISHA (JP) | 2013-01-03 | — | — | US | disclosed |
| US-20130001542-A1 | ORGANIC LIGHT-EMITTING DEVICE | CANON KABUSHIKI KAISHA (JP) | 2013-01-03 | — | — | US | disclosed |
| US-20120132901-A1 | PYRENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE USING THE SAME | CANON KABUSHIKI KAISHA (JP) | 2012-05-31 | — | — | US | disclosed |
| US-20120132901-A1 | PYRENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE USING THE SAME | CANON KABUSHIKI KAISHA (JP) | 2012-05-31 | — | — | US | disclosed |
| US-20110295047-A1 | METHOD FOR PRODUCING COMPOUND | CANON KABUSHIKI KAISHA (JP) | 2011-12-01 | — | — | US | disclosed |
| WO-2011122384-A1 | ORGANIC LIGHT-EMITTING DEVICE | CANON KABUSHIKI KAISHA (JP) | 2011-10-06 | — | — | WO | disclosed |
| WO-2011018951-A1 | PYRENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE USING THE SAME | CANON KABUSHIKI KAISHA (JP) | 2011-02-17 | — | — | WO | disclosed |
| WO-2010061953-A1 | METHOD FOR PRODUCING COMPOUND | CANON KABUSHIKI KAISHA (JP) | 2010-06-03 | — | — | WO | disclosed |
| US-20100059739-A1 | ORGANIC ELECTROLUMINESCENCE ELEMENT, IMAGE DISPLAY DEVICE, AND IMAGING APPARATUS | CANON KABUSHIKI KAISHA (JP) | 2010-03-11 | — | — | US | disclosed |
| US-20100059739-A1 | ORGANIC ELECTROLUMINESCENCE ELEMENT, IMAGE DISPLAY DEVICE, AND IMAGING APPARATUS | CANON KABUSHIKI KAISHA (JP) | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110295047-A1 | METHOD FOR PRODUCING COMPOUND | ARL1, AR, ARF1 | ESR2 441/4885ESR1 698/4885HSD17B1 265/4885 |
| US-20120132901-A1 | PYRENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE USING THE SAME | PPOX, CYP1A1, CYP3A4 | ESR2 70/4885ESR1 9/4885HSD17B1 470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.